Study #2016-1029
A Phase 1 Immunotherapy Study of Evofosfamide in Combination with Ipilimumab in Patients with Advanced Solid Malignancies
MD Anderson Study Status
Not Accepting
Treatment Agent
Evofosfamide, Ipilimumab
Description
An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV) negative squamous cell carcinoma of head and neck that have failed to respond to standard therapy, progressed despite standard therapy, for which standard therapy does not offer the potential for increased survival.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
Study phase:
Phase I
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.